METTL16 and colorectal cancer: These findings suggest that by modulating PD-L1 expression, METTL16 can influence the response to immune checkpoint inhibitors, highlighting its potential as a therapeutic target to overcome resistance to immune checkpoint inhibitor therapy in patients with colorectal cancer.51